Benign cancer in liver. IASGO Bangkok
Conținutul
Lancet Oncol ; 20 8 :Aug. This phase trial evaluated the safety and efficacy of the hafnium oxide HfO2 nanoparticle NBTXR3 activated by benign cancer in liver versus radiotherapy alone as a pre-operative treatment in patients with locally advanced soft-tissue sarcoma. Sarc is a phase randomised, multicentre, international trial.
Patients had to have a WHO performance status of benign cancer in liver a life expectancy of at least 6 months. Randomisation was stratified by histological subtype myxoid liposarcoma vs others. This was an open-label study.
The primary endpoint was benign cancer in liver proportion of patients with a pathological complete response, assessed by a central pathology review board following European Organisation for Research and Treatment of Cancer guidelines in the intention-to-treat population full analysis set.
Safety analyses were done in all patients who received at least one puncture and injection of NBTXR3 or at least one dose of benign cancer in liver.
REVIEW-URI
This study is registered with ClinicalTrials. Two patients in the NBTXR3 group and one patient in the radiotherapy group were excluded from the efficacy analysis because they were subsequently discovered to be ineligible; thus, a total of patients were analysed for the primary endpoint in the intention-to-treat full analysis set 87 in the NBTXR3 group and 89 in benign cancer in liver radiotherapy alone group.
No treatment-related deaths occurred.
